Investors & Media

Press Release

Printer Friendly Version View printer-friendly version
<< Back
bluebird bio Announces Transition of Chief Financial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 25, 2016-- bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that Jim DeTore, chief financial officer, has decided to leave the company, effective March 18, 2016. In conjunction with this announcement, bluebird bio is appointing Jeffrey Walsh as chief financial and strategy officer, effective March 1, 2016. Mr. Walsh previously served as chief operating officer of bluebird bio since May 2011.

“As bluebird bio continues advancing toward commercialization, we are putting more focus on our commercial organization to best serve our future needs. In addition, we are combining several strategic functions under Jeff’s leadership to maintain our strategic focus in a rapidly evolving field. As a result, Jim has decided to pursue opportunities outside the company,” said Nick Leschly, chief bluebird. “Jim has been a valued member of the bluebird executive team, and his contributions have been instrumental to our growth. His efforts have positioned us very well both financially and strategically to continue our pursuit of life-changing treatments for patients. On behalf of the bluebird bio team, I want to thank Jim for his significant contributions and wish him the best in his future endeavors.”

Prior to joining bluebird bio, Mr. Walsh served as chief business officer of Taligen Therapeutics. He has also held senior business development, finance and operations roles at PathoGenesis Corp. (acquired by Chiron Corporation), AllScripts Healthcare Solutions, EXACT Sciences and Inotek Pharmaceuticals.

About bluebird bio, Inc.
With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and cancer. bluebird bio’s gene therapy clinical programs include its Lenti-D™ product candidate, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin® BB305 product candidate, currently in three clinical studies for the treatment of transfusion-dependent ß-thalassemia, also known as ß-thalassemia major, and severe sickle cell disease. bluebird bio’s oncology pipeline is built upon the company’s leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird bio’s lead oncology program, bb2121, is an anti-BCMA CAR T program partnered with Celgene. bb2121 is currently being studied in a phase 1 trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies with the potential for use across the company’s pipeline.

bluebird bio has operations in Cambridge, Massachusetts, Seattle, Washington, and Paris, France.

LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.

Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the advancement of, and anticipated development and regulatory milestones and plans related to the Company’s product candidates and clinical studies. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk of cessation or delay of any of the ongoing or planned clinical studies or development activities for our product candidates, the risk of a delay in the enrollment of patients in the Company’s clinical studies, the risk that the results of previously conducted studies involving similar product candidates will not be repeated or observed in ongoing or future studies involving current product candidates, the risk that our collaborations will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.

Availability of other information about bluebird bio
Investors and others should note that we communicate with our investors and the public using our company website (www.bluebirdbio.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. You can also connect with us on Twitter @bluebirdbio, LinkedIn or our YouTube channel. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in bluebird bio to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include other social media channels than the ones described above. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Source: bluebird bio, Inc.

bluebird bio, Inc.
Investors and Media:
Manisha Pai, 617-245-2107
mpai@bluebirdbio.com
or
Pure Communications, Inc.
Media:
Dan Budwick, 973-271-6085

Investor Contact

Manisha Pai

Sr. Director, Investor Relations

(617) 245-2107

investor@bluebirdbio.com


Media Contacts

Elizabeth Pingpank

Associate Director, Corporate Communications

(617) 914-8736

EPingpank@bluebirdbio.com


Dan Budwick

Senior Vice President, Media Relations

Pure Communications Inc.

(973) 271-6085

dan@purecommunicationsinc.com